日本抗体薬物複合体（ADC）市場規模、競合情勢、トレンド分析レポート：タイプ別（カドサイラ、エンヘルツ、アドセトリス、パデセブ、トロデルヴィ、ポリヴィ）、ターゲット別（HER2、CD22、CD30）： 2025年から2033年までの機会分析および業界予測

レポートID : ROJP0825788 | 最終更新 : 2025年08月 | フォーマット : : :

Japan Antibody Drug Conjugate Adc Market Report - Table of Contents

1. INTRODUCTION

2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY

4. VOICE OF CUSTOMER

5. MARKET DYNAMICS

5.1 Market Overview
5.2 Market Drivers
- 5.2.1 Increasing Prevalence of Cancer Pushing the Growth of the Japanese Market
5.3 Market Restraints
- 5.3.1 High Development Cost & Manufacturing Complexities May Impede the Growth of the Market
5.4 Market Opportunity
- 5.4.1 Advances in Antibody-Drug Conjugate (ADC) Technology Pushing the Growth of the Market in Japan
5.5 Porter's Five Force Analysis
- 5.5.1 Bargaining Power of Buyers/Consumers
- 5.5.2 Bargaining Power of Suppliers
- 5.5.3 Threat of New Entrants
- 5.5.4 Threat of Substitute Products
- 5.5.5 Intensity of Competitive Rivalry

6. MARKET SEGMENTATION (Market Size by Value - USD)

6.1 By Type
- 6.1.1 Kadcyla
- 6.1.2. Enhertu
- 6.1.3. Adcetris
- 6.1.4. Padcev
- 6.1.5. Trodelvy
- 6.1.6. Polivy
6.2 By Target
- 6.2.1 HER2
- 6.2.2. CD22
- 6.2.3 CD30
- 6.4.3 Residential

7. COMPETITIVE LANDSCAPE